| 1 |
Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug |
|
| | Samareh Azeredo da Silveira,Andrew F. Shorr | | | Antibiotics. 2020; 9(2): 94 | | | [Pubmed] [Google Scholar] | | | 2 |
CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial |
|
| | Pierre-François Laterre,Gwenhael Colin,Pierre-François Dequin,Thierry Dugernier,Thierry Boulain,Samareh Azeredo da Silveira,Frédéric Lajaunias,Antonio Perez,Bruno François | | | The Lancet Infectious Diseases. 2019; | | | [Pubmed] [Google Scholar] | | | 3 |
Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain |
|
| | Antoni Torres,Matteo Bassetti,Tobias Welte,Simone Rivolo,Edit Remak,Carmen Peral,Claudie Charbonneau,Jennifer Hammond,Wajeeha Ansari,Santiago Grau | | | Journal of Medical Economics. 2019; : 1 | | | [Pubmed] [Google Scholar] | | | 4 |
CAL02 Liposomes and Other Antitoxins |
|
| | Samareh Azeredo da Silveira,Antonio Perez | | | Clinical Pulmonary Medicine. 2018; 25(3): 84 | | | [Pubmed] [Google Scholar] | | | 5 |
Improving the fate of severely infected patients: the promise of anti-toxin treatments and superiority trials |
|
| | Samareh Azeredo da Silveira,Antonio Perez | | | Expert Review of Anti-infective Therapy. 2017; 15(11): 973 | | | [Pubmed] [Google Scholar] | |
|
